Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: meibomian gland dysfunction therapies - Glaukos Corporation/Attillaps Pharmaceuticals

Next Previous
Drug Profile

Research programme: meibomian gland dysfunction therapies - Glaukos Corporation/Attillaps Pharmaceuticals

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Attillaps Pharmaceuticals
  • Developer Attillaps Pharmaceuticals; Glaukos Corporation
  • Class Anti-inflammatories; Eye disorder therapies; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Meibomian gland dysfunction

Most Recent Events

  • 28 Nov 2025 No recent reports of development identified for preclinical development in Meibomian gland dysfunction in USA (Ophthalmic)
  • 01 Oct 2021 Meibomian-gland-dysfunction therapeutic candidates are licensed to Glaukos to research, develop, manufacture and commercialise globally for the treatment of Meibomian-gland-dysfunction
  • 01 Oct 2021 Preclinical trials in Meibomian gland dysfunction in USA (Ophthalmic) prior to October 2021 (Attillaps Pharmaceuticals website, October 2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top